Aurobindo Pharma Limited has received final approval from the USFDA to manufacture and market Rivaroxaban Tablets USP, 2.5 mg, which is equivalent to Janssen Pharmaceuticals Inc.’s XARELTO®.

The US regulator has cleared 2.5mg tablet formulations of rivaroxaban – the active ingredient in Xarelto – from Sun Pharma subsidiary Taro Pharmaceuticals and Lupin, according to the Orange ...

Generic drugmaker Aurobindo Pharma has received final approval from the U.S. Food and Drug Administration (U.S. FDA) to manufacture and market Rivaroxaban Tablets USP, 2.5 mg. The approved ...

Bayer and Janssen’s novel oral anticoagulant (NOAC) Xarelto has a new string to its bow after the FDA approved it to prevent blood clots in acutely ill medical patients. The drug, marketed by ...